CLEC7A Antibodies

Structure of CLEC7A

The protein encoded by the CLEC7A gene has a molecular weight of approximately 28 kDa, and there are certain differences among different species. This protein mainly functions as a pattern recognition receptor and initiates the immune response by recognizing components of fungal cell walls.

The CLEC7A protein consists of 247 amino acids. Its extracellular segment forms a compact spherical conformation through C-type lectin folding. This protein contains a carbohydrate recognition domain, which is stabilized by calcium ions for ligand binding conformation. The intracellular segment of the receptor has an ITAM-like motif, which can recruit the Syk kinase to initiate signal transduction. The hydrophobic residues in the transmembrane region ensure the correct localization of the receptor on the membrane, while the membrane proximal stem loop region promotes receptor oligomerization and enhances the binding affinity with fungal ligands.

Fig. 1 The interaction between Clec7a (cyan) and MD2 (pink).¹

Key structural properties of CLEC7A:

• Extracellular C-type lectin-like domain
• Calcium ion-dependent ligand binding site
• Hydrophobic anchor sequence in the transmembrane region
• Intracellular ITAM-like motif mediating signal transduction

Functions of CLEC7A

The main function of CLEC7A is to recognize the components of fungal cell walls and trigger an immune response. Additionally, it is involved in regulating inflammatory responses and the activation of adaptive immunity.

The ligand binding curve of CLEC7A exhibits typical saturation characteristics, which is different from the nonlinear activation pattern of immune receptors. This reflects its high affinity and rapid response characteristics as a pattern recognition receptor for fungal β-glucans.

Applications of CLEC7A and CLEC7A Antibody in Literature

1. Wan, Hanxi, et al. "Clec7a Worsens Long‐Term Outcomes after Ischemic Stroke by Aggravating Microglia‐Mediated Synapse Elimination." Advanced science 11.36 (2024): 2403064. https://doi.org/10.1002/advs.202403064

This study reveals that after ischemic stroke, the expression of CLEC7A in microglia is upregulated, enabling it to phagocytose excitatory synapses. Regulating CLEC7A can reduce synaptic loss and improve neurological function. CLEC7A may interact with the neuronal MD2, making it a potential therapeutic target for IS.

2. Ma, Jie, et al. "Clec7a drives gut fungus-mediated host lipid deposition." Microbiome 11.1 (2023): 264. https://doi.org/10.1186/s40168-023-01698-5

The research reveals that intestinal fungi regulate obesity through the CLEC7A signaling pathway. Supplementing mice with specific fungi can prevent obesity, while activating CLEC7A accelerates obesity, and knocking out this gene can resist obesity. The fungal-CLEC7A axis is a potential target for metabolic regulation.

3. Wang, Yaqiong, et al. "Clec7a expression in inflammatory macrophages orchestrates progression of acute kidney injury." Frontiers in immunology 13 (2022): 1008727. https://doi.org/10.3389/fimmu.2022.1008727

The study reveals that macrophages after renal IRI can be classified into four subgroups. Clec7a+ M1 cells have strong pro-inflammatory phagocytic ability, while Clec7a- M2 cells promote repair. Regulating the expression of Clec7a can improve renal function, suggesting that it is a new target for the treatment of AKI.

4. Yang, Shubing, et al. "Clec7a signaling in microglia promotes synapse loss associated with tauopathy." International Journal of Molecular Sciences 26.7 (2025): 2888. https://doi.org/10.3390/ijms26072888

The study found that the Clec7a-SYK signaling axis was activated in the tau protein disease model, and it mediated the clearance of synapses by microglia. Inhibiting Clec7a could alleviate neuroinflammation, restore synaptic function and improve memory. This suggests that Clec7a is a potential therapeutic target for synaptic damage associated with tau protein diseases.

5. Wang, Jinchao, et al. "CLEC7A regulates M2 macrophages to suppress the immune microenvironment and implies poorer prognosis of glioma." Frontiers in immunology 15 (2024): 1361351. https://doi.org/10.3389/fimmu.2024.1361351

The study found that CLEC7A is highly expressed in gliomas and is positively correlated with malignancy, serving as an independent prognostic factor. It affects the immune microenvironment by regulating the chemotaxis and polarization of M2-type macrophages, and is expected to become a new target for immunotherapy in gliomas.

Creative Biolabs: CLEC7A Antibodies for Research

Creative Biolabs specializes in the production of high-quality CLEC7A antibodies for research and industrial applications. Our portfolio includes monoclonal and polyclonal antibodies tailored for ELISA, Flow Cytometry, Western blot, immunohistochemistry, and other diagnostic methodologies.

• Custom CLEC7A Antibody Development: Tailor-made solutions to meet specific research requirements.
• Bulk Production: Large-scale antibody manufacturing for industry partners.
• Technical Support: Expert consultation for protocol optimization and troubleshooting.
• Aliquoting Services: Conveniently sized aliquots for long-term storage and consistent experimental outcomes.

For more details on our CLEC7A antibodies, custom preparations, or technical support, contact us at email.